Clinical trials: COPD Patients
COPD
Evaluation the Effectiveness of a Telemonitoring Program in a Cohort of COPD Patient With Frequent Readmissions
Observational non-randomized study with an intervention cohort from Hospital Galdakao-Usansolo with 119 patients and a control cohort from Hospital Cruces with 78 patients.
- Trial name
- telEPOC (NCT02528370)
- Testing
- telEPOC
- Volunteers
- 197 people
- Sponsor
- Dr. Cristobal Esteban
Chronic Obstructive Pulmonary Disease (COPD)
Aclidinium/Formoterol Fixed Combination Dose Finding Study
The study seeks to determine the optimal dose of the Aclidinium/Formoterol combination for investigation in Phase III clinical trials
- Trial name
- NCT00626522
- Testing
- Aclidinium bromide and formoterol
- Where
- 9 sites in Australia, Czechia and 2 more
- Volunteers
- 808 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
The aim of this real world study is to assess the safety profile of tiotropium/olodaterol (Tio/Olo).
- Trial name
- NCT05393245
- Testing
- Tiotropium+Olodaterol, Spiolto Respimat, Long-acting muscarinic antagonists (LAMAs)
- Where
- China
- Volunteers
- 19,467 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU
The purpose of this study is to show the efficacy and safety of formoterol for the maintenance treatment of patients with COPD compared with placebo in patients in Japan and in European countries during 12 weeks.
- Trial name
- OCEAN (NCT00628862)
- Testing
- Formoterol Turbuhaler® 4.5mg, Formoterol Turbuhaler® 9 mg
- Where
- 47 sites in Bulgaria, Japan and 3 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)
The objective of the study is to observe the effect of adherence to once-daily administered long-acting bronchodilators (long-acting ß2-agonists [LABAs] / long-acting muscarinic antagonists [LAMAs]) on patients health related…
- Trial name
- NCT01937390
- Testing
- Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation, Indacterol 300 µg, Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule
- Where
- Germany
- Volunteers
- 645 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Noninvasive Ventilation
Determination of the Prevalence and Severity of Expiratory Flow Limitation in Chronic Obstructive Pulmonary Disease Patients
Expiratory Flow Limitation (EFL) occurs when the airways become compressed, which usually results when the pressure outside the airway exceeds the pressure inside the airway.
- Trial name
- NCT03851510
- Testing
- Vector ventilator, Resmon Pro
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Philips Respironics
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple dose of Zabofloxacin Tablet 400 mg.
- Trial name
- DW224-III-3 (NCT01658020)
- Testing
- Zabofloxacin, Moxifloxacin
- Where
- South Korea
- Volunteers
- 345 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Chronic Obstructive Pulmonary Disease
A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease
Objective: Chronic obstructive pulmonary disease (COPD) is a disease with significant morbidity and incurs heavy utilization of healthcare resources.
- Trial name
- NCT01108835
- Testing
- Comprehensive care programme
- Where
- Hong Kong
- Volunteers
- 180 people
- Sponsor
- Chinese University of Hong Kong
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a progressive disorder of the lung parenchyma and airways, which is the third-leading cause of death in the USA.
- Trial name
- Quercetin (NCT01708278)
- Testing
- Quercetin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan
Chronic Obstructive Pulmonary Disease
Integrating Care After Exacerbation of COPD
This clinical trial is designed to determine whether an intervention that provides information to primary care providers about gaps in care for their patients recently discharged from hospital for COPD can reduce hospital…
- Trial name
- InCasE (NCT02021955)
- Testing
- guideline treatment recommendations
- Where
- 2 sites in United States
- Volunteers
- 717 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients
This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one inhalation b.i.d, or standard COPD therapy.
- Trial name
- NCT01047553
- Testing
- Formoterol (OT)
- Where
- 27 sites in Japan
- Volunteers
- 251 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.
The primary objective of this study is to assess pharmacokinetics of tiotropium + olodaterol fixed-dose combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) delivered by the RESPIMAT inhaler after 3 weeks once daily treatment in Japanese…
- Trial name
- NCT01703845
- Testing
- Tiotropium (high dose) + Olodaterol, Tiotropium (low dose) + Olodaterol
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
COPD
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER® device.
- Trial name
- NCT00557466
- Testing
- indacaterol, formoterol, short acting β2- agonist
- Where
- 75 sites in Argentina, Belgium and 15 more
- Volunteers
- 568 people
- Sponsor
- Novartis
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main…
- Trial name
- EPIC (NCT00097773)
- Testing
- Tobramycin solution for inhalation (TOBI), Oral ciprofloxacin
- Where
- 54 sites in United States
- Volunteers
- 304 people
- Sponsor
- Seattle Children's Hospital
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD
Randomized,double-blind,multicenter,multinational,parallel-group,Phase III study to demonstrate the superiority of the triple fixed combination of beclometasone + formoterol + glycopyrrolate (BDP/FF/GB) administered via…
- Trial name
- TRILOGY (NCT01917331)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate, Beclometasone/Formoterol
- Where
- Hungary
- Volunteers
- 1,368 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease (COPD)
An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.
- Trial name
- CRESCENDO (NCT05492877)
- Testing
- Mitiperstat (AZD4831)
- Where
- 101 sites in United States, Argentina and 12 more
- Volunteers
- 381 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)
The purpose of this study is to compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are…
- Trial name
- INSTEAD (NCT01555138)
- Testing
- Indacaterol, Salmeterol
- Where
- 94 sites in Argentina, Colombia and 7 more
- Volunteers
- 581 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.
- Trial name
- NCT00856193
- Testing
- NVA237
- Where
- 2 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Novartis